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Abstract
Fibrinogen like protein 1(Fgl1) is a secreted protein with mitogenic activity on primary hepatocytes. Fgl1 is expressed in the
liver and its expression is enhanced following acute liver injury. In animals with acute liver failure, administration of
recombinant Fgl1 results in decreased mortality supporting the notion that Fgl1 stimulates hepatocyte proliferation and/or
protects hepatocytes from injury. However, because Fgl1 is secreted and detected in the plasma, it is possible that the role
of Fgl1 extends far beyond its effect on hepatocytes. In this study, we show that Fgl1 is additionally expressed in brown
adipose tissue. We find that signals elaborated following liver injury also enhance the expression of Fgl1 in brown adipose
tissue suggesting that there is a cross talk between the injured liver and adipose tissues. To identify extra hepatic effects,
we generated Fgl1 deficient mice. These mice exhibit a phenotype suggestive of a global metabolic defect: Fgl1 null mice
are heavier than wild type mates, have abnormal plasma lipid profiles, fasting hyperglycemia with enhanced
gluconeogenesis and exhibit differences in white and brown adipose tissue morphology when compared to wild types.
Because Fgl1 shares structural similarity to Angiopoietin like factors 2, 3, 4 and 6 which regulate lipid metabolism and
energy utilization, we postulate that Fgl1 is a member of an emerging group of proteins with key roles in metabolism and
liver regeneration.
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Introduction
Fibrinogen like protein 1 (Fgl1 also called HRFEP-1, also called
hepassocin) was initially identified as an overexpressed transcript
in hepatocellular carcinoma [1] and as a transcript enriched in
regenerating rodent livers [2]. Analysis of multiple human and rat
tissues and human cell culture lines suggest that Fgl1 is mostly
expressed in the liver or hepatocyte derived cell lines [1,3]. Both
human and rodent FGL1 contain a canonical signal recognition
sequence and not surprisingly, the protein is detected in culture
media of expressing cells and in the plasma of rodents and humans
[3,4,5].
Recombinant Fgl1 stimulates tritiated thymidine uptake in
rodent primary hepatocytes at a level similar to that of hepatocyte
mitogens such as epidermal growth factor [3]. In addition,
administration of purified recombinant Fgl1 to rodents with toxin
induced fulminant liver failure reduces mortality [6]. Although
there is a basal level of Fgl1 expression in rodent livers, there is
marked induction of expression after liver injury as occurs with
70% partial hepatectomy (PH) [2,7], which parallels the injury
mediated elevation in IL-6 [8]. Indeed, treatment of Hep G2 cells
with IL-6 leads to robust expression and subsequent enhanced
secretion into the culture media [4] and either the sub-cutaneous
injection of turpentine (an inducer of IL-6) or the intraperitoneal
injection of recombinant IL-6 into rodents leads to enhanced
plasma levels of Fgl1 ([4,9] and CU, unpublished). In addition to
IL-6, recent studies have shown that hepatocyte nuclear factor 1-
alpha (HNF1a), regulates the expression of Fgl1 in vivo and that
deletion of a specific HNF1a site abrogates Fgl1 promoter
activation [9]. Taken together, these studies suggest that Fgl1 is
a liver secreted factor that acts in an autocrine/paracrine fashion
to enhance hepatocyte proliferation and/or protect hepatocytes
from injury.
Fgl1 is structurally similar to Angiopoietin like factors
(ANGPTLs). It contains an N-terminal signal recognition peptide,
a potential N-terminal coil-coil domain, a C-terminal fibrinogen
related domain (FReD) and multiple cysteines presumably used for
inter and intra molecular disulfide bonds. Recent data suggest that
a number of ANGPTL proteins, specifically ANGPTL 2, 3, 4 and
6 play regulatory roles in lipid and energy metabolism. For
example, mice lacking Angptl3 or Angptl4 have low plasma
triglyceride and cholesterol concentrations [10,11,12]. Multiple
lines of evidence show that Angptl3 and Angptl4 regulate plasma
triglyceride levels through the inhibition of lipoprotein lipase and/
or hepatic lipase [11,13,14] and/or through stimulation of lipolysis
in adipose tissue [15,16]. The deletion of Angptl2 in mice leads to
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Lastly, Angptl6
2/2 mice are obese, hyperinsulinemic and accumu-
late significant amounts of triglycerides in the liver and skeletal
muscle [18], whereas transgenic mice that overexpress Angptl6 in
the liver, remain lean on a high fat diet [18]. The structural
similarity between these proteins and Fgl1 raises the intriguing
possibility that Fgl1 may not only regulate liver proliferative
processes but may also play a role in lipid metabolism and energy
utilization.
In this study we show that Fgl1 is expressed not only in liver but
also adipose tissues. Remarkably, expression in brown adipose
tissue is enhanced following 70% PH in mice. We generated an
Fgl1 knock out mouse and find that it is larger than age matched
wild type control mice, exhibits fasting hyperglycemia, changes in
lipid metabolism, structural defects in brown and white adipose
tissues and impaired expression of brown and white fat genes. We
conclude that Fgl1 is a liver and adipose tissue regulatory factor
and that it may serve as novel factor to interrogate the link
between adipocyte function and hepatocyte proliferation.
Methods
The Fgl1 Null Mouse
The Fgl1 gene contains 8 exons spanning over 24 kilobases
(kb)of genomic DNA. The initiator ATG resides in the second
exon. To disrupt Fgl1, we replaced exons 2 and 3 with a lox-neo-
lox (LNL) cassette which removes the initiator ATG and abolishes
the secretory signal recognition peptide. The resulting targeting
vector was electroporated into PTL1 (129B6) hybrid ES cells.
Several ES cells containing the targeting construct were identified
by PCR. Male chimeras were bred to C57BL/6 females for germ-
line transmission of the Fgl1 null allele. Mice heterozygous for the
Fgl1 allele (Fgl1
+/2) were then intercrossed to generate homozy-
gous Fgl1
2/2 mice on a mixed 129/B6 genetic background.
Animals were genotyped and allelic composition identified
through the generation of a 215-bp (wild type) or 322-bp
(disrupted allele) upon PCR amplification. Primers for genotyping
were Fgl1
+/+: forward 59-AGCTGCCTGTGT-
TATTTCCTCTCA-39 and reverse 59-CCAGGGAGCCATTT-
TATTTATCCAA-39. Fgl1
2/2 : forward 59-AC-
Figure 1. Fgl1 in hepatic and brown adipose tissue. A) mRNA levels of Fgl1 in the liver at baseline (0 h) and at 24 h and 48 h after PH. Note the
increased expression after PH. P=0.002 between 0 h and 24 h and less than 0.0001 between 0 h and 48 h after PH. The difference between levels at
24 h and 48 h is not significant. B) mRNA levels of Fgl1 in brown adipose tissue (BAT) at baseline and at 24 h and 48 h after partial hepatectomy. Fgl1
is detectable in BAT prior to injury but expression is enhanced after PH. P=0.026 between 0 and 24 h and P=0.013 between 0 and 48 h after PH. The
difference between levels at 24 h and 48 h is not significant. n=3 for samples in 1A and B. C) Gel electrophoresis of amplified cDNA from BAT at
baseline and at 24 h and 48 h after PH. Cyclophilin A is the loading control. D) Comparison of BAT Fgl1 levels pre and post PH with hepatic Fgl1 levels
at baseline. Samples are normalized to hepatic Fgl1 at 100%. Fgl1 in BAT is 0.4%, 2.6% and 3.4% of hepatic levels at baseline and at 24 h and 48 h
after PH (P,0.0001).
doi:10.1371/journal.pone.0058084.g001
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GGACGTAAA CTCCTCTTCAGACCTA-39.
Animals
Ethics Statement: All animal experiments were performed
according to institutional guidelines of Harvard Medical School.
All protocols with animal experimentation conformed to criteria
outlined in the National Institutes of Health ‘‘Guide for the Care
and Use of Laboratory Animals.’’ Protocols were reviewed and
approved by the animal use committee of Harvard Medical School
(protocol number 04193). Except where otherwise specified, the
mice were fed normal chow diet (LabDiet, Brentwood, MO) with
free access to food and water and were 3–4 months old males.
Tissue Harvest and Surgery
Mice were weighed prior to sacrifice. Following euthanasia,
liver, white adipose from the inguinal fat pads, brown adipose,
cardiac and quadriceps skeletal muscle tissues were removed and
weighed. In some instances the length of the animal from the nose
to the anus was determined. For 70% PH, surgeries were
performed on Fgl1
+/+ and Fgl1
2/2 mice as previously described
[19] with the left and median lobes of the liver were removed. This
tissue was used as the pre-partial hepatectomy sample. At 24 h and
48 h after PH, animals were euthanized; liver and brown adipose
tissue was removed, immersed in 10% formalin or frozen in liquid
nitrogen and stored at 280uC for later analysis. For determination
of bromo deoxyuridine (BRDU) incorporation, animals were
injected with 100 mg/kg of BRDU dissolved in sterile PBS by
intraperitoneal (i.p.) route, 2 h prior to tissue harvest. Formalin
fixed samples were then processed for immunohistochemistry. Of
note, except where noted animals had free access to food and
water prior to tissue harvest.
Western Immunoblots
Briefly, liver tissue was homogenized in RIPA buffer (25 mM
Hepes PH 7.4, 150 mM NaCl, 1% Triton X-100, 1% deoxycholic
acid, 0.1% SDS, 2 mM EDTA) with a tissue grinder. The
resulting homogenate was spun at 13,000 RPM. The supernatant
was transferred to clean tubes, the protein concentration was
determined and lysates were then denatured with Lammeli sample
buffer. Approximately 60 mg of protein was loaded per lane on a
10% SDS-PAGE. Western blots were performed as previously
described [20].
Nucleic Acid Assays
PCR assays (qualitative and quantitative) were performed as
previously described [21]. mRNA levels were determined relative
to cyclophilin A. Table S1 in File S1 shows primer sequences used
for these assays.
Plasma Triglyceride, Cholesterol and Free Fatty Acid
Concentrations
Plasma was obtained from mice wild type and null for Fgl1.
Plasma triglyceride, cholesterol and free fatty acids were deter-
mined using reagents kits (Wako, Richmond, VA) as per
manufacturer’s instruction. Fast protein liquid chromatography
(FPLC) analysis was performed as previously reported [22].
Glucose Tolerance Tests
Fgl1
+/+ and Fgl1
2/2 mice were fasted overnight (14–16 h) with
free access to water. After obtaining baseline blood glucose levels
each mouse received 1 mg/g of body weight of 20% glucose
(Sigma, St Louis, MO) by i.p. injection. Blood glucose readings
were then obtained 15, 30, 60, 90, 120, and 180 min after initial
injection of glucose. After 180 min, mice were returned to their
cages.
Pyruvate Tolerance Tests
Fgl1
+/+ and Fgl1
2/2 mice were fasted overnight (14–16 h) with
free access to water. After obtaining baseline blood glucose levels,
each mouse received 2 g/kg of body weight i.p. injection of
sodium pyruvate (Sigma, St. Louis, MO). Blood glucose readings
were then obtained 15, 30, 60, 90, 120, and 180 min after initial
injection of glucose. After 180 min mice were returned to their
cages.
Insulin Tolerance Tests
Fgl1
+/+ and Fgl1
2/2 mice were fasted for 16 h before testing.
Baseline blood glucose levels were obtained then each mouse was
injected with 1 U/kg of body weight of insulin (Eli Lilly,
Indianapolis, IN). Blood glucose readings were obtained at 15,
30, 45 and 60 min after initial injection of insulin.
Plasma Insulin Concentrations
Plasma insulin concentrations were determined by ELISA
(Joslin Diabetes and Endocrinology Research Center Specialized
Assay Core; supported in part by NIH 5P30 DK36836, Joslin
Diabetes Center, Boston, MA, USA). Homeostatic Model of
Assessment (HOMA) was determined using the formula: fasting
glucose (mmol/L) 6fasting insulin (mU/L)/22.5 [23].
Measurement of Lipid Droplet Size
Lipid droplet area was measured with ImageJ software 1.46r
(National Institutes of Health, Bethesda, MD). After appropriate
thresholding, 406 magnification H/E images were converted to
binary format. The watershed function was used to discriminate
between individual droplets. Droplet size was measured with the
droplet analysis function and area was converted to mm2 after
determination of image scale. Data represented at mean droplet
size+SEM. Differences between groups were assessed with non-
paired Student’s t-test using Graphpad Prism statistical software
(Graphpad Software Inc, La Jolla, CA).
Food Consumption
3 month old mice wild type for (n=4) and devoid of Fgl1 (n=8)
were housed individually and food intake measured daily. Prior to
the onset of the experiments all cage clippings were removed and
replaced with DACB liner paper (GQF manufacturing, Savannah,
GA). Food was provided in a food cup and all animals had free
access to water. Everyday for 18 days, total food consumed per day
was determined by taking the difference between the weight of
food placed in the cup and the weight of food remaining, including
food particles on the ground. Animals were also weighed daily.
Analysis of covariants was used to determine if there is any
correlation between food intake and genotype.
Indirect Calorimetry
Fgl1
+/+ and Fgl1
2/2 mice were individually housed in
calorimetric chambers (Columbus Instruments, Columbus, OH)
with free access to food and water. After a 24 h acclimation
period, food consumption and gas exchange was determined. The
rates of oxygen consumption (VO2, ml/kg/h) and of CO2
production (VCO2, ml/kg/h) were determined for individual
mice and then used to determine day, night and total averages for
each variable. The respiratory quotient (RER) was then calculated
as the VCO2/VO2. Heat (kcal/h) was calculated as (caloric value
Fgl1 and Metabolism
PLOS ONE | www.plosone.org 3 March 2013 | Volume 8 | Issue 3 | e58084Figure 2. The liver in the Fgl1 knockout mouse. A) Fgl1 transcript is absent in the livers of the knockout mouse pre and post PH. Note the
expected induction of Fgl1 in the wild type mouse after PH (P,0.01 for Fgl1 at baseline and 48 h after PH, n=3 per group) B) Fgl1 protein is absent in
the livers of the knockout mouse before and after PH while it is detectable at baseline and induced after PH in the wild type mouse. C) Fgl1
2/2 mice
are larger than wild type mates as early as three weeks after birth (P,0.0001, n=5 for each group). D) Representative graph of change in weight over
time for Fgl1
+/+ (n=8 for first 4 weeks, n=4 for last three weeks) and Fgl1
2/2 (n=9 for first 4 weeks and n=8 for last three weeks). E) Liver mass is
not different between Fgl1
+/+ and Fgl1
2/2 mice (n=9 for each group). F) Liver weight to body weight ratio is smaller for Fgl1
2/2 mice (P=0.008,
n=9). G) Marked lipid accumulation in the livers of Fgl1
2/2 mice after PH. Top: gross images of representative livers from Fgl1
+/+ (left) and Fgl1
2/2
(right). Arrows indicate remnant liver lobes. Middle: H&E images at 406magnification of liver sections from Fgl1
+/+ and Fgl1
2/2 mice at 48 h post PH
and bottom: similar H&E images at 96 h post PH. Note the resolution of steatosis in the Fgl1
2/2 mouse by 96 h after PH. H) Triglyceride (TG) content
of liver extracts from Fgl1
+/+ and Fgl1
2/2 mice before and after PH. The difference between Fgl1
2/2 and Fgl1
+/+ at 48 h after PH is significant
(P=0.014, n=3–5 per cohort for experiments). I) mRNA levels of lipid regulatory genes at 48 h after PH (P=0.011, 0.014 and 0.037 respectively for
PPARa, PPARd and FATP5 but is otherwise non significant). n=4 for Fgl1
+/+ except FATP5 where n=3 per group. n=5 for Fgl1
2/2.
doi:10.1371/journal.pone.0058084.g002
Fgl1 and Metabolism
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Activity was determined by series of beam breaks per mouse and
was calculated as average beam break per hour. VO2, VCO2,
RER, heat and activity were calculated as light (0700 h –1900 h)
and dark (1901 h –0659 h) and total (0700 h –0659 h) averages
per mouse and then the Fgl1
+/+ and Fgl1
2/2 mice were averaged
and reported as mean and SEM on graphs using Excel and
Graphpad Prism 5.
18F-fluorodeoxyglucose Uptake
Mice were injected with 350 mCi
18F-fluorodeoxyglucose
(
18FDG). Animals were sacrificed and tissue samples of heart,
muscle, white adipose and brown adipose were collected and
washed with PBS. Tissues were weighed and radioactivity was
measured using a Wallac Wizard Gamma Counter (GMI Inc,
Ramsey, MN) to obtain the % injected dose per gram (%ID/g).
Statistical Analysis
Data presented in the manuscript are means. Error bars
represent SEM. For GTT, ITT and PTT tests, all data for the
area under the curve analysis (AUC) were normalized to basal
glucose levels of each mouse. Statistical significances was
determined using two tailed unpaired student t test, one way
and two way ANOVA on a Graphpad Prism 5. Mixed
regression analysis was performed on SAS version 9.3 (SAS
Institute, Cary, NC).
Results
Basal and Inducible Expression of Fgl1 in Adipose Tissue
An analysis of the expression of FGL1 in 50 distinct adult and
fetal human tissues revealed liver-specific expression with the
exception of low-level expression in the pancreas [3]. Another
evaluation of 12 rat tissues and 9 human cancer cell lines showed
that FGL1 was similarly liver-specific in its expression [1].
However, these studies did not include adipose tissue, which is
of interest given the structural similarity with ANGPTL proteins,
which include members that regulate lipid and energy metabolism.
Consequently, we performed qPCR assays for Fgl1 mRNA in
liver, brown and white adipose tissues of mice. As anticipated, Fgl1
was expressed in the liver, and was upregulated 11 fold at 24 h
(P=0.002) and 7 fold at 48 h (P,0.0001) following PH
(Figure 1A). We also detected low levels of Fgl1 mRNA in brown
adipose tissue (Figure 1B (left most bar) and 1C (lanes 1and 2)),
and in white adipose tissue (Figure S2 in File S1, 2
nd bar from the
left and the first three lanes of the inset, lower panel). Interestingly,
Fgl1 mRNA is upregulated 6.5 fold at 24 h (P=0.026) and 8.5 fold
at 48 h (P=0.013) in brown adipose tissue following PH (Figure 1B
and C) suggesting that the injury response of Fgl1 in the liver is
sensed in brown adipose tissue. Despite this upregulation of Fgl1,
mRNA levels remain lower in brown adipose tissue pre and post
partial hepatectomy (250, 38 and 29 fold lower at baseline, 24 h
and 48 h after PH respectively, P,0.0001 at each time point)
Figure 3. Plasma lipid, cholesterol and free fatty acid levels in the Fgl1 null mouse. A) There is no significant difference in steady state
plasma TG levels of Fgl1
+/+ and Fgl1
2/2 mice. B) Free fatty acid levels are decreased in the Fgl1 null mouse (P=0.001). C and D) Plasma cholesterol
levels are levels are lower as determined by total cholesterol (P=0.003) and FPLC analysis. n=5 per group.
doi:10.1371/journal.pone.0058084.g003
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PLOS ONE | www.plosone.org 5 March 2013 | Volume 8 | Issue 3 | e58084Figure 4. Glucose metabolism in the Fgl1 null mouse. A) Fgl1
2/2 mice have fasting hyperglycemia (P=0.005, n=10 for Fgl1
+/+ and n=8 for
Fgl1
2/2). B) Glucose tolerance tests of fasted 3 month old mouse. The graph represents a plot of plasma glucose versus time after i.p. administration
of glucose. The superimposed panel represents plots of average area under the curve (AUC) for each mouse. The baseline was set as the mean pre-
glucose administration plasma level. The difference is glucose levels as determined from the AUC is significant (P=0.002, n=4 per group). C) Insulin
tolerance test on 3 month old fasted mouse shows a similar rate of decline of glucose levels between the Fgl1
+/+ and Fgl1
2/2 mice. AUC calculations
after normalizing for baseline glucose for the first 45 min of the test shows no differences between Fgl1 containing and deficient mice (n=5 per
group). D) Insulin levels are not different between Fgl1
+/+ and Fgl1
2/2 mice. E) HOMA scores are not different for Fgl1
+/+ and Fgl1
2/2 (n=5 for Fgl1
+/+
and 4 for Fgl1
2/2). F) Graph of glucose levels following administration of pyruvate to fasted mice. Inset is AUC calculation which shows a difference in
glucose levels over the duration of the experiment (P=0.029, n=5 per group).
doi:10.1371/journal.pone.0058084.g004
Fgl1 and Metabolism
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experiments show that that Fgl1 is expressed in adipose tissues
and that signals elaborated during liver injury regulates its
expression in both the liver and brown adipose tissue.
Figure 5. Structure, content and activity of adipose tissues in the Fgl1 null mouse. A) Representative H&E stains (406magnification) of
brown adipose tissue. Lipid droplets are larger in Fgl1
2/2 mice. B) Quantitation of lipid droplet size show significant difference between Fgl1
+/+ and
Fgl1
2/2 mice (P=0.011, n=5 per group). C) Expression of brown adipose genes. Note the paradoxical up regulation of DiO2 and UCP1 (P=0.002 and
0.0001 respectively. n=11 per group except for Perilipin and HSL where n=5 and 6 respectively). D)
18FDG incorporation into BAT. The % uptake
represents the uptake of injected dose per gram of tissue. Note the marked decrease in radioisotope uptake in BAT (P=0.05, n=5 per group). E).
Representative H&E stains (406magnification) of white adipose tissue. Lipid droplets are larger in Fgl1
2/2 mice. F) Quantitation of number of cells
per HPF shows smaller number of white adipose cells in Fgl1
2/2 (P=0.005, n=5). G) Expression of white adipose genes. Glut4, leptin and perilipin are
significantly down regulated (*) with a P,0.04 for each. P for ATGL (#) is 0.06. n=4–6 mice per group.
doi:10.1371/journal.pone.0058084.g005
Fgl1 and Metabolism
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To initiate studies on the physiological functions of Fgl1, we
generated a mouse null for Fgl1. The Fgl1 gene comprises 8 exons
spanning more than 24 kb of genomic DNA. The initiator ATG
resides in the second exon. To disrupt Fgl1, we deleted exons 2 and
3 which removed the initiator ATG and abolished the secretory
signal recognition peptide (Figure S1A in File S1). Genotyping
confirmed the insertion of the neomycin cassette in the Fgl1
2/2
mouse (Figure S1B in File S1). To ascertain whether Fgl1 was
absent in the knockout mouse, we performed qPCR assays and
found that Fgl1 mRNA and protein were absent in the livers of
Fgl1
2/2 mice at baseline and after PH (Figure 2A and B). We also
observed that Fgl1 mRNA was absent from both brown and white
adipose tissues of the Fgl1
2/2 mice (Figure S2 in File S1). Despite
the loss of Fgl1 expression, Fgl1
2/2 mice appeared grossly normal
when compared to wild type mates except that they were
persistently heavier. This difference in size was obvious at 3
weeks, the earliest we could genotype our mice, at which point the
Fgl1 null mouse were 37% heavier than wild type mates
(Figure 2C, P,0.0001). We monitored a group of mice beginning
at 7 weeks and find that the size difference remains as the mice age
(Figure 2D). Indeed in a small cohort of mice we kept for 11
months this difference persisted (not shown). Considering Fgl1’s
presumptive role in liver proliferation, we carefully examined liver
tissue, but observed no differences between the livers of Fgl1
+/+
and Fgl1
2/2 mice by: i) liver weight (1.15+/20.28 grams versus
1.03+/20.05 grams respectively, Figure 2E), ii) histologic analysis
by hematoxylin and eosin staining (not shown), iii) immunohisto-
chemistry for PCNA and BRDU incorporation (not shown).
However we found that the liver weight to body weight ratio, a
quotient used to determine appropriate liver size for body weight
[24] is smaller in Fgl1
2/2 when compared to wild type mates
(Figure 2F, P=0.0081). These findings confirm that the Fgl1 mice
were not heavier as a result of increased liver size. At 48 h after
PH, Fgl1
2/2 livers appeared grossly steatotic (Figure 2G, top
panels). Histologic analysis demonstrated the presence of marked
macrovesicular steatosis following PH at 48 h (Figure 2E, compare
middle panel images) with resolution by 96 h (Figure 2G, compare
right middle panel to right lower panel). In addition, lipid analysis
showed that the triglyceride (TG) content of liver extract was
markedly elevated at 48 h post PH (Figure 2H, P=0.014). This
suggests that Fgl1 has lipid regulatory roles that became manifest
during recovery from liver injury. We next determined the
expression levels of hepatic lipid regulatory genes; lipolysis: hepatic
lipase (HL), oxidation: peroxisome proliferator-activated receptor
alpha (PPARa, PPARc1, PPARc2, PPARd and carnitine
palmitoyltransferase (CPT1)), fatty acid transport genes: cluster
of differentiation 36 (CD36), fatty acid transport protein 2
(FATP2) and FATP5 and lipid synthetic genes: fatty acid synthase
(FAS) and acetyl-CoA carboxylase (ACC) at baseline and at 48 h
after PH. With the exception of PPARd (P=0.016) which is
upregulated in the Fgl1
2/2 liver, we found no differences in the
expression of these cohort of genes at baseline (Figure S3 in File
S1). At 48 h post PH however, we see a persistent difference in the
expression of PPARd (P=0.011) in addition to enhanced
expression of another lipid oxidation gene PPARa (P=0.014)
and lipid transport protein, FATP5 (P=0.037) in the Fgl1
2/2
mouse (Figure 2I). These data suggest that Fgl1 regulates a
pathway involved in hepatic lipid metabolism and that with its loss,
lipid regulatory differences become phenotypically obvious during
liver regeneration.
Decreased Plasma Cholesterol and Free Fatty Acid Levels
in the Fgl1
2/2 Mouse
Considering the phenotype of the Fgl1
2/2 mice, the structural
similarity between FGL1 and ANGPTL3 and 4 and the role of
these proteins in regulating plasma lipids, we ascertained the lipid
profile in the liver and plasma of fasted wild type and Fgl1 null
mice. Hepatic concentrations of triglycerides (Figure 2G, left side
bars), cholesterol and free fatty acids (not shown) were not
significantly different in chow fed mice. In addition, plasma levels
of plasma triglycerides were similar between the wild type and
mutant mice (Figure 3A). However, plasma free fatty acid and
cholesterol concentrations were decreased in the Fgl1
2/2 mice
(Figure 3B and 3C, P=0.001 and 0.003 respectively). There were
no clear genotype-dependent differences in the VLDL containing
fraction (Figure 3D), but HDL cholesterol content in the Fgl1
2/2
mice showed a decrease that was consistent with the reductions in
total plasma cholesterol shown in Figure 3C. These data are in
keeping with findings in mice with targeted disruption of Angptl3
and Angptl4 where in the fasted state triglyceride levels were
unchanged but cholesterol levels were decreased [11].
Fasting Hyperglycemia in the Fgl1
2/2 Mouse
We next asked whether there were differences in glucose
metabolism between the Fgl1
+/+ and Fgl1
2/2 mice. First we
determined blood glucose after an overnight fast and found more
profound fasting hyperglycemia in the Fgl1
2/2 mice (Figure 4A,
P=0.005) at 4 months of age. We next subjected these mice to
glucose tolerance tests (GTT). Fgl1
2/2 mice exhibited reduced
glucose tolerance, as evidenced by more profound elevation in
plasma glucose concentrations. By 60 min after administration of
glucose there was already marked difference in plasma glucose
levels between the wild type and the mutant mice (Figure 4B). We
determined the area under the curve (AUC) for each animal using
basal levels of glucose and the average AUC for each Fgl1
+/+ and
Fgl1
2/2 mice and found statistically significant differences in
response to the administered glucose load (Figure 4B and
superimposed, P=0.002). We next asked whether these effects
on glucose were due to differences in sensitivity to insulin and or
due to differences in plasma insulin levels. We performed insulin
tolerance tests (ITT) following an overnight fast on 4 month old
mice. We found a similar magnitude in the reduction of glucose
levels after exogenous administration of insulin, suggesting that
both Fgl1
+/+and Fgl1
2/2 mice were equally sensitive to admin-
istered insulin (Figure 4C). In support of this, we determined the
area under the curve for each mouse and found no significant
difference between the wild type and the Fgl1 null mouse
(Figure 4C, superimposed). In addition, we measured insulin
levels and found no differences (Figure 4D) and estimates of insulin
sensitivity by homesostatic model assessment (HOMA) showed no
Table 1. Length and tissue mass of Fgl1
+/+ and Fgl1
2/2 mice.
Fgl1
+/+ Fgl1
2/2 P value
Weight (grams) 21.91+/20.49 25.26+/21.27 0.039
Length (millimeters) 89.60+/20.68 93.40+/20.40 0.001
Liver (grams)* 1.15+/20.03 1.03+/20.05 NS
Heart (grams) 0.11+/20.01 0.14+/20.01 NS
Quadriceps muscle
(grams)
0.19+/20.01 0.21+/20.03 NS
White adipose (grams) 0.24+/20.03 0.55+/20.11 0.021
Brown adipose (grams) 0.06+/20.01 0.09+0.01 NS
(n=5 for both cohorts except for liver (*) where n=9).
doi:10.1371/journal.pone.0058084.t001
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defects in GTT were due to a non insulin dependent process. We
next performed pyruvate tolerance test to ascertain if differences in
gluconeogensis may account for the increased glucose levels in the
Fgl1
2/2 mice. Figure 4F shows that Fgl1
2/2 mice have enhanced
glucose synthesis when compared to wild type mates. The
difference between the two cohorts is significant as determined
by the AUC (Figure 4F, inset, P=0.029).
Fgl1
2/2 Mice Exhibit Structural and Functional Defects in
Adipose Tissues
The difference in body weights between the Fgl1
+/+ and Fgl1
2/
2 mice is not due to an enlarged liver (Figure 2E and 2F). To
ascertain if increase in the weight of any organ accounted for the
difference in size we determined the weight of the quadriceps
muscle, cardiac muscle, inguinal white adipose tissue and brown
adipose tissue. We also determined the length of each mouse from
the nose to the anus. We found that there is a statistically
Figure 6. Food intake and indirect calorimetry. Scatter plot of average food intake versus average weight for individually housed Fgl1
+/+ (blue
squares, n=4) and Fgl1
2/2(red circles, n=8) taken daily over an 18 day period. Note that Fgl1
2/2 remain larger that wild types for the duration of the
experiment. B and C) Indirect calorimetric values for VO2 and VCO2 respectively and D) RER. The RER is significant irrespective of day and night cycles
(P=0.04 and 0.016 respectively) and over the entire 24 h (P=0.019). E) Heat generation is not significantly different and F) activity is not different
between the Fgl1 containing and deficient mice. n=6 for Figures 6B to 6F.
doi:10.1371/journal.pone.0058084.g006
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2/2
mouse longer than the Fgl1
+/+ mouse (93.40+/20.40 millimeters
versus 89.60+/20.68 respectively, P=0.001, Table 1). We also
found more white adipose tissue content in the Fgl1
2/2 mouse
(0.55 grams +/20.11 versus 0.24+/20.03 grams, P=0.021,
Table 1) which persists even after accounting for difference in
body weight. These data imply that the Fgl1
2/2 mice are longer
and fatter. Considering these data, we next examined white and
brown adipose tissues by hemotoxylin and eosin staining and
found differences between brown and white adipose tissue
morphology of Fgl1
+/+and Fgl1
2/2 mice. In mice lacking Fgl1,
we found that the brown adipose tissue contained larger lipid
droplets and had markedly reduced number of nuclei while the
wild type mice had small sized fat particles more typical of brown
fat (Figure 5A). Quantitative estimates confirm that the droplets in
the Fgl1
2/2 mice are larger (Figure 5B, P=0.011). We performed
qPCR assays to ascertain differences in lipogenic gene expression
between Fgl1
+/+ and Fgl1
2/2 mice. We found no differences in the
level of brown adipocyte differentiation genes; PR domain
containing 16 (PRDM16) and peroxisome proliferator-activated
receptor gamma co-receptor 1a (PGC1a) or in lipolysis regulatory
genes; hormone sensitive lipase (HSL), adipose triglyceride lipase
(ATGL), cell death inducing DFFA-like effector a (CIDEA) and
perilipin. Surprisingly, we find paradoxical up regulation of
uncoupling protein 1(UCP1) and iodothyronine deiodinase type
II (DiO2) in the brown adipose tissue of the Fgl1
2/2 mouse
(Figure 5C, P=0.0001 and 0.002 respectively). To elucidate
functional defects in brown adipose tissue of Fgl1
2/2 mice, we
administered
18FDG into mice and measured uptake by scintil-
lation counting. We found a marked decrease in
18FDG in brown
fat tissue of Fgl1
2/2 mice (Figure 5D, P=0.05). This suggests a
defect at the level of brown fat tissue either in its ability to
efficiently take up glucose or in its activity. In white adipose tissue
of the Fgl1 null mouse, we found larger fat containing cells when
compared Fgl1
+/+ mice (Figure 5E), supported by the a lower
number of white adipocytes per high power field in white adipose
tissue of the Fgl1
2/2 mouse (Figure 5F, P=0.005). We analyzed
white adipose tissue to ascertain differences in the expression of
regulatory genes. We found no significant differences in the
expression PPARa, sterol regulatory element binding protein 1c
(SREBP1c), fatty acid synthase (FAS) and HSL. We however find
suppression of Glut4, leptin and perilipin (Figure 5G, P,0.04 for
all three genes). These results suggest that there are structural,
molecular and functional differences in adipose tissue of mice that
express or lack Fgl1.
Food Consumption is Similar between Fgl1
+/+ and Fgl1
2/
2 Mice
Our Fgl1
2/2 mice are heavier and thus we wondered if the
increased size was due to increased food consumption. We
determined food consumption over an 18 day period for
individually housed mice by measuring daily food intake and
daily weights. Figure 6A shows that Fgl1
2/2 were heavier than
wild type mates through out the experiment. However, mean food
consumption per day was similar for both groups (3.32+/20.04 g
versus 3.29+/20.04 g for Fgl1
+/+and Fgl1
2/2 respectively).
Because there were multiple observations per individual mouse,
we performed mixed regression analysis (mixed effect models the
weight of subjects based upon the number of measurements and
their variability, and thus yield more appropriate standard errors
than linear regression). We used food intake as the dependent
variable and genotype as the independent variable, adjusted for
body weight at each measurement day. As expected, we found no
relationship between genotype and daily food intake (beta
coefficient for mutant versus wild type mice (20.088 g food,
P=0.21)). These data suggest that increased food intake is not the
reason for the larger size of the Fgl1
2/2mice. To determine
whether the Fgl1
2/2 and Fgl1
+/+ mice differed metabolically, we
used indirect calorimetry to determine oxygen consumption
(VO2), carbon dioxide generation (VCO2), the respiratory
quotient (RER) and heat exchange. We also determined activity
for each cohort. We found no differences in activity between the
wild type and Fgl1 null mouse (Figure 6F). We found statistically
insignificant but lower absolute values lower VO2 and VCO2 for
the Fgl1
2/2 mice irrespective of time of day (Figure 6B and C).
However, we found a significantly lower RER in the Fgl1
2/2 mice
during day light h, night time h and for the entire 24 h period
(Figure 6D, P=0.04, P=0.016 and P=0.019 respectively). These
data suggest that Fgl1 null mice were more dependent on fatty
oxidation for energy source when compared to the wild type
mates. We used the indirect calorimetric data to determine the
heat generation for each cohort and found no significant
differences between the two cohorts (Figure 6E).
Discussion
This study was designed to elucidate the functions of Fgl1, a
primarily liver secreted protein with mitogenic activity on
hepatocytes. We establish that Fgl1 has novel functions in glucose
metabolism and energy substrate utilization. The major findings
are: i) Fgl1was expressed in low levels in adipose tissue but that this
expression is augmented following liver injury ii) Fgl1 null mice
had lower fasting plasma concentrations of cholesterol and free
fatty acids iii) Fgl1 null mice exhibited fasting hyperglycemia and
enhanced hepatic glucose production iv) Fgl1 null mice were
heavier than wild type mates despite consuming similar amounts
of food.
Previous studies on Fgl1 have focused primarily on its role in
hepatocyte biology, showing that the protein is secreted by
hepatocytes, enhances tritiated thymidine incorporation into
hepatocytes, and rescues animals from liver failure [3,4,6]. In
the absence of liver injury, deletion of Fgl1 did not lead to any
gross hepatic defects, whereas following injury to the liver, there
were marked increases in hepatic triglyceride accumulation in the
Fgl1 null mouse, suggesting that metabolic stress may have
revealed this novel biological function of Fgl1. This was supported
by the observation that Fgl1 expression in brown adipose tissue is
enhanced following PH, similar in magnitude to its induction in
the liver following PH. These findings are in keeping with the
observations of Simek and colleagues from almost half a century
ago who suggested a crosstalk between adipose tissue and the liver
through regulated lipolysis during liver regeneration [25]. Whereas
the molecular mechanisms that underlie cross-talk between liver
and adipose tissue during liver regeneration remain largely
unknown, the profound hepatic steatosis observed in the Fgl1
null mice during regeneration suggests a key regulatory role for
Fgl1 in linking liver regeneration with adipose tissue function.
In the absence of Fgl1, we found decreased cholesterol and free
fatty acid concentrations. This is in keeping with observations from
the natural loss of Angptl3 in the KK/San mouse showing
decreased cholesterol and free fatty acids [10,16] and the with
targeted disruption of Angptl3 and Angptl4 which also exhibit low
plasma cholesterol levels [11]. Thus, loss of Fgl1 phenocopies
plasma lipid concentrations in mice devoid of Angptl3 and Angptl4.
These effects are believed to be mediated by the ability of both
ANGPTL proteins to inhibit clearance of VLDL and chylomicron
triglycerides into peripheral tissues or through stimulation of
adipose tissue lipolysis resulting in increased free fatty acid levels
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intrigued by the fact that adipocytes from brown and white
adipose tissue of the Fgl1
2/2 mice have comparably larger sized
fat containing cells. We also found decreased mRNA levels of the
lipolytic enzyme ATGL, in white adipose tissue. These data
suggest that impairment in adipose tissue lipolysis may be the
principal culprit that leads to decreased plasma free fatty acid
concentrations. In addition, the accumulation of triglycerides in
the liver of the Fgl1 null mouse during recovery from liver injury
and the differential regulation of FATP5 which enhances transport
of fatty acids into the liver and of PPARa and d, two factors whose
activity are regulated by products of lipolysis [26,27,28] support
the notion that Fgl1 may regulate hepatic lipid concentrations
during liver regeneration.
Mice deficient of Fgl1 have fasting hyperglycemia, similar
insulin sensitivity and enhanced gluconeogenesis. We suggest that
these impairments likely result from physiologic differences in both
hepatic and adipose tissues. Because insulin levels and response to
exogenous insulin administration are similar, we speculate that
enhanced glucose production occurs through an insulin indepen-
dent mechanism. Because adipocytes have been implicated in the
regulation of glucose homeostasis, our finding of defects in their
structure and in gene expression suggests that they may contribute
to the differences in glucose levels between the Fgl1
+/+ and Fgl1
2/
2 mice. In brown fat, we find decreased
18FDG uptake suggesting
that glucose uptake into this adipose tissue is also reduced. In white
adipose tissue, we found significant down regulation of Glut4, a
gene whose loss in adipose tissue results in hyperglycemia and
impaired glucose handling [29,30]; leptin a gene whose product
enhances peripheral glucose uptake [31] and perilipin, a white
adipose protein whose over expression protects from diet induced
obesity and improves glucose tolerance [32]. Thus the hypergly-
cemia in the Fgl1 null mouse likely occurs as a result of increased
hepatic production and decreased uptake into adipose tissues.
Loss of Fgl1 results in an increase in size of the mice despite
similar food consumption. However, quantitative estimates of
tissue mass show that Fgl1
2/2 mouse have larger white adipose
tissue mass. We believe that the increased white adipose content
likely accounts for some of the difference in size and suggests that
the Fgl1
2/2 mouse is fatter than it wild type counterpart. In
addition, we speculate that the Fgl1
2/2 mice have defects in
brown adipose function and may be hypometabolic because 1)
they eat the same as wild type mates despite a larger size 2) they
have morphologically more white adipose-like lipid droplets 3)
they have reduced uptake of
18 FDG, a marker for brown fat
function 4) they have paradoxical upregulation of DiO2, an
enzyme that regulates brown adipose thyroid hormone levels and
5) of UCP1 a canonical brown adipose protein and a biochemical
marker of brown adipose activation. The decreased
18FDG uptake
in the absence of differences insulin levels suggest an insulin
independent uptake of glucose into brown fat, typical of this tissue
[33,34] and implies a defect in brown adipose tissue function at
this level. In addition the paradoxical upregulation of UCP1
transcripts suggest that Fgl1 may help regulate appropriate
activation of UCP1 and that in its absence transcript levels are
regulated as an adaptive response. Lastly, published data suggest
that loss of DiO2 results intra adipose hypothyroidism, despite
systemic euthyroid state [35] and we speculate that the paradox-
ical upregulation of DiO2 mRNA levels suggests a defect in brown
adipose tissue function.
A number of issues raised by the studies presented remain
unanswered. Firstly, previous studies have suggested that Fgl1 acts
as a paracrine factor on hepatocytes [9]. However we have
previously shown that Fgl1 is present in the plasma [4] suggesting
that it may have hormonal action on distant targets. The current
studies show that Fgl1 transcript is present in low levels in adipose
tissues implying that that low levels of protein secreted by adipose
tissues could have paracrine effects. Regardless, we are cognizant
of the fact that adipose tissues may also be hormonally affected by
hepatic derived Fgl1. Studies on the specific effect of Fgl1 on
adipose tissue will have to await the identification of a receptor
and/or through tissue specific ablation of Fgl1. Alternatively,
in vitro studies of brown adipocyte differentiated cells from Fgl1
+/+
and Fgl1
2/2 mice may yield insight into the exact role of Fgl1 in
this adipose tissue. Secondly, the mechanisms governing hepatic
steatosis during liver regeneration in the Fgl1
2/2 mice remain
incompletely defined. Our results suggest that there is increased
fatty acid transport into hepatocytes likely mediated by FATP5.
However, there is concurrent increase in PPARa and PPARd
levels which would be expected to result in enhanced oxidation of
lipids and resolution of steatosis. We suspect that given that the
steatosis is transient and resolved by 96 h after PH, the increase in
oxidative gene expression may be a result of but not the cause of
the steatosis. Future experiments with detailed time course analysis
will allow us to identify the mechanisms that govern this hepatic
defect. Thirdly, despite a higher white adipose content, Fgl1
2/2
mouse have lower RERs suggesting more dependence on fat for
metabolism. This may be an artifact of stress response induced by
independent housing of mice for these experiments and not
reflective of free living condition or of group-housed animals.
Indeed, we found that when mice were moved from a group
housing to independent cages to determine food consumption
shown in Figure 6A, they lost weight and were then sluggish with
regards to increased weight during the subsequent 18 days.
Although there was no significant difference in average weight loss
between the two groups, it is possible that the stress of isolation
leads to more dependence on fat based metabolism and to lower
RER in the Fgl1
2/2.
Taken together, our data suggests a previously unrecognized
role for Fgl1 in regulation of intermediate metabolism. In addition,
we propose Fgl1 as a new angiopoietin like factor given i)
structural conservation between Fgl1 and ANGPTLs ii) a similar
tissue expression with hepatic and adipose tissue expression iii)
similar defects in plasma lipids levels with low free fatty acids and
cholesterol in Fgl1 similar to Angptl3 and 4 knockouts and iv)
impaired glucose metabolism as seen in the Angptl6 knockout.
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